Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai*, Tianhui Zhou*, Xiaogang Xiang, Jie Lu, Haiguang Xin (✉), Qing Xie (✉)

Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

© Higher Education Press 2021

Abstract The coronavirus disease 2019 (COVID-19) has caused global public health and economic crises. Thus, new therapeutic strategies and effective vaccines are urgently needed to cope with this severe pandemic. The development of a broadly neutralizing antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is one of the attractive treatment strategies for COVID-19. Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodies when SARS-CoV-2 enters human cells through an interaction between the S protein and the angiotensin-converting enzyme 2 expressed on various human cells. A single monoclonal antibody (mAb) treatment is prone to selective pressure due to increased possibility of targeted epitope mutation, leading to viral escape. In addition, the antibody-dependent enhancement effect is a potential risk of enhancing the viral infection. These risks can be reduced using multiple mAbs that target nonoverlapping epitopes. Thus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral surface may be the most effective therapeutic strategy.

Keywords neutralizing antibody; antibody cocktail; SARS-CoV-2; COVID-19; therapeutic strategy

Introduction

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic, severely threatening human lives and the global economy [1]. Clinical evidence-based medicine, including guidelines based on strong evidence and the results of randomized clinical trials on COVID-19 treatment, is still evolving. While several antiviral drugs have been developed [2,3], the monoclonal antibody (mAb) therapy that can neutralize SARS-CoV-2 may be an alternative, innovative, and effective method to cope with the coronavirus infection. However, selective pressure may occur during any treatment of coronavirus infection with a single mAb because of the likelihood of the virus undergoing mutation, thereby escaping the detection by mAbs. By developing a cocktail therapy comprising a combination of multiple mAbs that target nonoverlapping epitopes, the risk of mutational escape can be reduced, and the therapeutic efficacy may be improved.

Neutralizing antibody development

How does SARS-CoV-2 infect humans? Virus particles enter human cells through the interaction of the spike (S) protein and the angiotensin-converting enzyme 2 (ACE2) expressed on various human cells. New viral particles are prepared inside infected cells and are released outside of the cells. In the same way, these particles can infect normal cells. Thus, if the surface of the virus S protein is the key, the ACE2 is the matching lock. If the interaction of key and lock proteins is blocked, the virus cannot replicate in large numbers. Antibodies that can block this function are called neutralizing antibodies.

Neutralizing antibodies are a class of antibodies that can prevent cells from being infected by pathogens. Once this phenomenon is achieved, the disease can be controlled, and the remaining pathogens can be slowly eliminated by the body’s immune system. Neutralizing antibodies can effectively target pathogens and are a key target in vaccine development. Studies have accumulated numerous data in the development of neutralizing monoclonal antibodies to
treat Ebola virus infections, such as Mab114, REGN–EB3, and ZMapp infections [4]. Currently, neutralizing antibodies is one of the most promising therapeutic modalities among several new coronavirus drugs under development.

Antigen-enriched B cells expressing the ACE2 receptor are isolated, and antibodies with different binding sites are screened out on the basis of the cross-reaction with SARS-CoV-2. The mechanism of the cocktail therapy of neutralizing antibodies for treating SARS-CoV-2 infection is shown in Fig. 1 [5–7].

Choosing a broadly neutralizing antibody against SARS-CoV-2 is a promising strategy for treating COVID-19. However, not all neutralizing antibodies are directed against the receptor-binding domain (RBD) [8]. Chi et al. [9] have identified the 4A8 antibody from convalescent patients with COVID-19, and this antibody binds to the N-terminal domain (NTD) of the SARS-CoV-2 S protein instead of the RBD. The identification of this antibody indicates that neutralizing antibodies act via diverse mechanisms. Thus, the NTD of the S protein may be a potential target for generating neutralizing antibodies to treat COVID-19. Pinto et al. [10] have described the S309 monoclonal antibody, which can effectively neutralize SARS-CoV-2 by binding to the RBD of the S glycoprotein. Cao et al. [11] have used the high-throughput single-cell RNA and VDJ sequencing methods to identify SARS-CoV-2-neutralizing antibodies from the antigen-enriched B cells of 60 convalescent patients and successfully identified 14 effective neutralizing antibodies, of which the BD-368-2 is the most effective. Another study has revealed that owing to its unique binding epitope, the binding of BD-368-2 to the S protein RBD is not affected by its spatial location. Irrespective of the “up” or “down” conformation of RBD, the BD-368-2 can bind to the RBD and completely block the binding of the S protein trimer to the ACE2 receptor [12]. In a recent study conducted before the COVID-19 pandemic, Kreer et al. [13] have performed the deep sequencing of naïve B cells from 48 healthy individuals and identified light chain and/or heavy chain precursor sequences with the SARS-CoV-2-neutralizing activity. These gene fragments encode effective neutralizing antibodies, suggesting that protective antibodies can be easily induced by vaccines.

Notably, anti-SARS-CoV-2 antibodies can exacerbate COVID-19 via a mechanism referred to as the antibody-dependent enhancement (ADE) [14]. Previous vaccine studies have warned of clinical safety risks associated with ADE in humans, which may lead to the failure of vaccine trials. ADE occurs in viral infections through different mechanisms, such as increased viral infection and replication or enhanced inflammation and a pathological immune response [15]. Coronaviruses have now spread across
species and become highly pathogenic. Moreover, coronaviruses can rapidly spread within a population. In addition, the virus can mutate, thereby posing an enormous challenge to the development of antiviral drugs.

**Concept and benefits of an antibody cocktail therapy**

The concept of cocktail therapy is first used for HIV infections. By combining three or more antiviral drugs, resistance to a drug can be reduced, thereby suppressing viral replication to the maximum extent, delaying disease progression, and improving the quality of life of patients [16]. The combination therapy has been successfully used in the field of oncology aside from viral infection treatments, and several new combination therapies comprising targeted therapy drugs have achieved clinical success [17,18]. In addition to approved antiviral drugs, mAbs are the leading candidates in vaccine development due to advances in the mAb technology [19].

**Clinical practice with antibody cocktail therapies**

Twenty registered clinical trials on COVID-19 treatment with neutralizing antibodies are either recruiting patients or have been completed, of which eight clinical trials are phase 2, 3, and 4 trials. Table 1 summarizes the eight registered clinical trials of neutralizing mAbs with therapeutic potential against SARS-CoV-2 reported so far, and trial results will be available soon.

Recently, Jones *et al.* have announced that in a randomized, double-blind, placebo-controlled phase 2 clinical trial, the cocktail therapy of neutralizing antibodies LY-CoV555 and LY-CoV016 can significantly reduce viral load and disease symptoms in patients with mild and moderate COVID-19 [20]. In the high-risk subgroup of patients with age > 65 years or BMI > 35 kg/m², the combination therapy can reduce the proportion of patients who are hospitalized or require emergency treatment from 13.5% to 0%. Results show that high-risk patients with

| Table 1 | Eight registered clinical trials of neutralizing mAbs with therapeutic potential against SARS-CoV-2 |
|---------|--------------------------------------------------|
| Clinical trial identifier | Study type | Estimated enrollment | Subjects | Treatment | Primary objectives |
| NCT04425629 | Randomized/ double-blind study | 2104 | Ambulatory patients with COVID-19 | Low-dose REGN10933 + REGN10987, high-dose REGN10933 + REGN10987 | To evaluate the clinical efficacy of REGN10933 + REGN10987 compared with placebo |
| NCT04426695 | Randomized/ double-blind study | 2970 | Hospitalized adult patients with COVID-19 | REGN10933 + REGN10987 | Proportion of patients with treatment-emergent serious adverse events |
| NCT04452318 | Randomized/ double-blind study | 2000 | Asymptomatic adults with SARS-CoV-2 infection | REGN10933 + REGN10987 | Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and signs and symptoms of SARS-CoV-2 infection during the efficacy assessment period |
| NCT04427501 | Randomized/ double-blind study | 800 | Patients with mild to moderate COVID-19 | LY3819253 (LY-CoV555) or LY3819253 + LY3832479 (LY-CoV016) | Change in SARS-CoV-2 viral load from baseline to day 11 |
| NCT04545060 | Randomized/ double-blind study | 1360 | Nonhospitalized patients with COVID-19 | Monoclonal antibody VIR-7831 | Proportion of participants who have progression of COVID-19 until day 29 |
| NCT04390464 | Randomized/ open-label study | 1167 | Admitted pre-ICU patients with COVID-19 | Ravulizumab (monoclonal antibody that binds to the terminal complement protein C5) or baricitinib (antirheumatic drug) | Time to incidence of the composite endpoint of death, mechanical ventilation, ECMO, cardiovascular organ support, or renal failure |
| NCT04634409 | Randomized/ double-blind study | 500 | Participants with mild to moderate COVID-19 | LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) | Percentage of participants with SARS-CoV-2 viral load higher than 5.27 |
| NCT04381936 | Randomized/ open-label study | 15 000 | Patients with COVID-19 | Drug: lopinavir–ritonavir Drug: corticosteroid Drug: hydroxychloroquine Drug: azithromycin Biological: convalescent plasma Drug: tocilizumab Biological: immunoglobulin Drug: synthetic neutralizing antibodies | All-cause mortality (within 28 days after randomization) |
COVID-19 are more likely to benefit from the cocktail therapy. Junshi Biology and the Chinese Academy of Sciences have cooperatively developed the neutralizing antibody JS016 (LY-CoV016). Eli Lilly has obtained the authorization from Junshi Biology outside Greater China. LY-CoV555 is a neutralizing antibody developed by Eli Lilly, AbCellera, and the National Institute of Allergy and Infectious Diseases. The Regeneron Pharmaceuticals has used humanized VelocImmune mice and peripheral blood from patients who have recovered from COVID-19 to isolate a single B cell for locating the epitope on the RBD of the S protein on SARS-CoV-2. Researchers have combined two SARS-CoV-2 virus monoclonal antibodies with strong neutralizing ability and do not identify overlapping epitopes in the S protein to reduce the risk of treatment failure due to the epitope mutation. Researchers have referred to this cocktail therapy as “REGN–COV2” (REGN10933 + REGN10987) [21]. The deep sequencing reveals that the combination of two monoclonal antibodies can overcome the limitation of a single antibody, providing the possibility of “1 + 1 > 2.” The results of the clinical trial show that REGN–COV2 can significantly reduce the viral load in patients and shorten the time for relief from symptoms. After seven days of treatment, REGN–COV2 significantly reduces the viral load in seronegative patients [22]. Lilly and Regeneron have submitted a request for emergency use authorization for monotherapy and REGN–COV2, respectively, to the U.S. Food and Drug Administration (FDA) [20,22]. However, neither the therapeutic antibodies (i.e., LY3819253 and LY3832479) nor REGN–COV2 have been approved by the FDA, and these data are from the companies’ official website. The data have neither been peer reviewed nor officially published. Therefore, rigorous, objective, detailed, and reliable data are needed to verify the clinical reliability of these therapies.

Summary

The mechanism of the SARS-CoV-2 infection is not fully understood. The development of neutralizing antibodies against SARS-CoV-2 has some challenges, such as mutations in the less conservative region of the S1 subunit and the induction of ADE by non-neutralizing antibodies. In addition, monoclonal antibodies may not recognize different viral strains, and mutations in the virus can lead to viral escape [23]. The use of a cocktail therapy may help identify neutralizing and non-neutralizing epitopes on the surface of the virus that interact with human cells, thereby representing a promising therapeutic strategy. Finally, because antibodies are protein drugs, their production, transportation, and storage represent significant limitations in addition to the expense involved in their production. Thus, further research is needed before their large-scale applications.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81970514), the Shanghai Municipal Key Clinical Specialty (No. shlszdck01103), and the Shanghai Municipal Planning Commission of Science and Research Fund (No. 202040111).

Compliance with ethics guidelines

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, and Qing Xie declare that they have no conflict of interest. This manuscript does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References

1. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungehusak K, Wieler LH; WHO Strategic and Technical Advisory Group for Infectious Hazards. COVID-19: towards controlling of a pandemic. Lancet 2020; 395(10229): 1015–1018
2. Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas F, Hirani A, Khan IA, Anis K, Karim AH. Treatment options for COVID-19: a review. Front Med (Lausanne) 2020; 7: 480
3. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ding G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020; 369: m1849
4. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, Lusakibanza Manzo M, Nzolo D, Tshomba Oloma A, Ibanda A, Ali R, Coulibaly S, Levine AC, Grais R, Diaz J, Lane HC, Muyembe-Tamfum JJ; PALM Writing Group, Sivahera B, Camara M, Kojan R, Walker R, Dighero-Kemp B, Cao H, Mukumbayi P, Mbala-Kingebeni P, Ahuka S, Albert S, Bonnett T, Crozier I, Duvenlage M, Profitt C, Teitelbaum M, Moench T, Aboulhab J, Barrett K, Cahill K, Cone K, Eckes R, Hensley L, Herpin B, Higgs E, Ledgerwood J, Pierson J, Smolks M, Sow Y, Tierney J, Sivapalasingam S, Holman W, Gettinger N, Vallée D, Nordwall J; PALM Consortium Study Team. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381(24): 2293–2303
5. Ho M. Perspectives on the development of neutralizing antibodies against SARS-CoV-2. Antib Ther 2020; 3(2): 109–114
6. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367(6485): 1444–1448
7. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020; 382(17): 1653–1659
Neutralizing mAbs against SARS-CoV-2

8. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, Torres JL, Okba NMA, Claireaux M, Kerster G, Bentley AEH, van Haaren MM, Guerra D, Burger JA, Schermer EE, Verheul KD, van der Velde N, van der Kooi A, van Schooten J, van Breemen MJ, Bijl TPL, Sliepen K, Aartse A, Derking R, Bontjier I, Kootstra NA, Wiersinga WJ, Vidalgoess L, Haagmans BL, Ward AB, de Bree GJ, Sanders RW, van Gils MJ. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 2020; 369(6504): 643–650.

9. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020; 369(6504): 650–655.

10. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi M, Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, Du X, Bao L, Deng W, Zhao J, Pan L, Wang Y, Qiao L, Tan Y, Song L, Xie XS. Potent neutralization of SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell 2020; 182(4): 843–854.e12.

11. Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, Du X, Bao L, Deng W, Zhu H, Liu J, Nie J, Zheng Y, Liang H, Liu R, Gong S, Xu H, Yissimai A, Lv Q, Wang B, He R, Li X, Lv Q, Zhu H, Deng W, Xu Y, Wang Y, Qiao L, Tan Y, Song L, Wang G, Du X, Gao N, Liu J, Xiao J, Su XD, Du Z, Feng Y, Qin C, Qin C, Jin R, Xie XS. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 2020; 182(1): 73–84.e16.

12. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol 2020; 5(10): 1185–1191.

13. Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother 2020; 16(12): 3055–3060.

14. Cohen J. HIV/AIDS. Prevention cocktails: combining tools to stop HIV’s spread. Science 2005; 309(5737): 1002–1005.

15. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010; 60(3): 166–193.

16. Fedor H. Cocktails for cancer with a measure of immunotherapy. Nature 2016; 532(7598): 162–164.

17. Andrews CD, Huang Y, Ho DD, Liberatore RA. In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. Emerg Microbes Infect 2020; 9(1): 1523–1533.

18. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoven CM, Blackbourne JL, Heinz BA, Foster D, Higgs RE, Balasubramaniam D, Wang L, Bidshahi R, Kraft L, Wang Y, Zentiles S, Jepson KR, Goya R, Smith MA, Collins DW, Hinshaw SJ, Tycho SA, Pellacani D, Xiang P, Muthuraman K, Sobhasatir P, Pipper MH, Triana FJ, Hendle J, Pustilnik A, Adams AC, Berens SJ, Baric RS, Martinez DR, Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli HM, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JD, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart BC, Graham BS, Mascola JR, Hansen CL, Falcóner E. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv 2020; [Preprint] doi:10.1101/2020.09.30.318972.

19. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloka E, Fulton BO, Yan Y, Koon K, Patel K, Chung KM, Hermann A, Ullman E, Cruz J, Rafique A, Huang T, Fairhurst J, Libertiny C, Malbec M, Lee WY, Welsh R, Farr G, Pennington S, Deshpande D, Cheng J, Watty A, Bouffiard P, Babb R, Levenkova N, Chen C, Zhang B, Romero Hernandez A, Saotome K, Zhou Y, Franklin K, Sivapalasingam S, Lye DC, Weston S, Logue J, Haupt R, Frieman M, Chen G, Olson W, Murphy AJ, Stahl N, Yancopoulos GD, Kratzovs CA. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 2020; 369(6506): 1010–1014.

20. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Braun A, Kyrtos CA, Kim Y, Cook A, Kampman W, Kohli A, Sachdeva Y, Graber X, Kowal B, DiCiccoio T, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med 2021; 384(3): 238–249.